Recombinant human tissue kallikrein

DRUG3 trials

Sponsors

DiaMedica Therapeutics Inc

Conditions

Acute Ischemic StrokeAcute StrokeIschemic StrokeStroke

Phase 1

An Open Label, Phase 1b, Ascending Dose Study of DM199

CompletedNCT02868996

DiaMedica Therapeutics IncStroke

Start: 2016-09-30End: 2017-03-31Updated: 2017-12-07

Phase 2

Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

CompletedNCT03290560

DiaMedica Therapeutics IncAcute Ischemic Stroke

Start: 2018-01-19End: 2020-01-23Updated: 2022-03-31

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

RecruitingNCT05065216

DiaMedica Therapeutics IncAcute Stroke, Ischemic Stroke, Stroke

Start: 2021-11-07End: 2026-12-01Target: 728Updated: 2026-09-14

Related Papers

Safety and tolerability of Rinvecalinase Alfa (DM199) for acute ischemic stroke (ReMEDy1).

2025-11-06